Related Experiment Video

Updated: Jul 7, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Mitochondrial DNA polymorphisms and haplogroups in Parkinson's disease and control individuals with a similar genetic

Helen Latsoudis1, Cleanthe Spanaki1, Grigoris Chlouverakis2

  • 1Department of Neurology, University of Crete, Medical School, Voutes and Staurakia, 71103, Heraklion, Crete, Greece.

Journal of Human Genetics
|February 21, 2008
PubMed

Insights

No specific mitochondrial DNA (mtDNA) variations predispose to Parkinson's disease (PD). However, certain mitochondrial DNA single nucleotide polymorphisms (mtSNPs) and haplogroups may slightly influence PD risk in the Cretan population.

Area of Science:

  • Neurogenetics
  • Mitochondrial Biology
  • Epidemiology

Background:

  • Mitochondrial complex I deficiency is linked to Parkinson's disease (PD) pathogenesis.
  • No definitive mitochondrial DNA (mtDNA) variations have been identified as causative agents for impaired complex I activity in PD.
  • mtDNA polymorphisms (mtSNPs) and haplogroups are hypothesized to modify PD risk.

Purpose of the Study:

  • To investigate the association between specific mtSNPs, defining major European haplogroups, and Parkinson's disease risk.
  • To determine the distribution of ten mtSNPs and nine major European haplogroups in a well-defined Cretan population.

Main Methods:

  • Genotyping of ten mtSNPs in 224 PD patients and 383 controls of Cretan origin.
  • Analysis of haplogroup frequencies to assess potential associations with PD.
  • Stratification based on population origin to ensure genetic homogeneity and avoid admixture.

Main Results:

  • No single mtSNP or mtDNA haplogroup was found to significantly predispose individuals to Parkinson's disease in the Cretan cohort.
  • A trend towards underrepresentation of haplogroups J, T, U, I, and the UKJT supercluster was observed in PD patients compared to controls.
  • The potential protective effect of common mtSNPs against PD was found to be minor in this population.

Conclusions:

  • mtDNA haplogroups and specific mtSNPs do not appear to be major risk factors for Parkinson's disease in the genetically homogeneous Cretan population.
  • While certain haplogroups showed a non-significant trend, their role in PD pathogenesis requires further investigation in larger, diverse cohorts.
  • The study highlights the importance of population-specific genetic background in exploring the complex interplay between mtDNA and neurodegenerative diseases.

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...